In these blogs, we explore some of the biggest topics in breast cancer research. One of those topics is how the body’s biological clock is involved in breast cancer.
To celebrate our research successes of the past year our research communications officer, Edd, picked out his favourite discoveries and explains why they are so important.
Scientists, based at the Queen Mary University of London, have discovered a new mechanism that signals which Ductal Carcinoma in Situ (DCIS) tumours may progress to invasive breast cancer. This might help avoid unnecessary treatment for some women with DCIS in the future.
PARP inhibitors like olaparib are an exciting new avenue of targeted treatment for breast cancer patients with changes to the BRCA genes. Let’s look at the journey of olaparib from first experiments in the lab until now.
Researchers have identified a group of immune cells that could be targeted to develop new treatments for breast cancers that are resistant to chemotherapy.